Author | Sponsored Content


HER2+ mBC: DESTINY-Breast04 Trial

December 25, 2019

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

x